Celltrion Healthcare is set to launch Zymfentra, also known as Remsima SC internationally, the sole subcutaneous formulation of infliximab for autoimmune diseases, in the U.S. on February 29, 2024.

The launch comes nearly four months after the drug received marketing authorization from the FDA on October 20.

Johnson & Johnson, the creator of the original infliximab, Remicade, faced challenges in converting intravenous infliximab to a subcutaneous injection.

To ensure a successful market entry for Zymfentra, Celltrion Healthcare has submitted clinical data for the drug to the majority of Pharmacy Benefit Managers (PBMs) in the U.S.

Negotiations for preferred drug status are currently underway.

In addition to these efforts, Celltrion Healthcare has outlined plans to participate in key conferences throughout the coming year, starting with the Crohn's & Colitis Congress (CCC) in January, followed by Digestive Disease Week (DDW) in May, the American College of Gastroenterology (ACG) in October, and the American College of Rheumatology (ACR) in November. This strategic approach aims to actively communicate Zymfentra's advantages to crucial stakeholders in the autoimmune disease sector and drive prescription expansion.

To further enhance outreach, Celltrion Healthcare will conduct targeted patient engagement activities, expanding communications with various patient organizations in the U.S. This initiative aims to increase prescribing preferences for Zymfentra.

Recognizing Zymfentra as a pivotal product in its journey toward achieving $12 trillion in sales by 2030, Celltrion Healthcare said it would sustain successful prescription expansion in the U.S. by effectively communicating the strengths of Zymfentra with patients suffering from inflammatory bowel disease.